Panacea Biotec brings unique Indian CB

Pharma company brings unusual structured CB.
Panacea Biotec, one of IndiaÆs top-three pharmaceutical companies, has sold $100 million worth of highly-structured convertible bonds through Merrill Lynch to raise cash for its future expansion in India and offshore.

The five-year bonds, which were split into two equal-sized tranches, have two unusual features, which together make this a unique deal in the Indian market. Most notably, the conversion price will be fixed only six months from the issue date and there is also a mandatory conversion feature after six months, subject to a 125% hurdle, for Tranche 1 and after 12 months, subject to a 130% hurdle, for Tranche 2.

One observer notes that this deal will have an inverse relationship to the...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222